Get the Stockscreener App
2.965
0.84%
-0.025
After Hours:
3.04
0.075
+2.53%
Lixte Biotechnology Holdings Inc stock is traded at $2.965, with a volume of 76,364.
It is down -0.84% in the last 24 hours and up +1.89% over the past month.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
See More
Previous Close:
$2.99
Open:
$2.96
24h Volume:
76,364
Relative Volume:
1.13
Market Cap:
$25.80M
Revenue:
-
Net Income/Loss:
$-4.08M
P/E Ratio:
-2.5215
EPS:
-1.1759
Net Cash Flow:
$-2.58M
1W Performance:
+1.89%
1M Performance:
+1.89%
6M Performance:
-41.40%
1Y Performance:
+143.03%
1-Day Range:
$2.85
$3.0201
1-Week Range:
$2.60
$3.12
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
2.965 | 26.02M | 0 | -4.08M | -2.58M | -1.1759 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - USA Today
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - TipRanks
Market Fear: Can Lixte Biotechnology Holdings Inc. Equity Warrant be recession proofFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Lixte Biotechnology Raises CEO Compensation Amid Leadership Support - TipRanks
Lixte (NASDAQ: LIXT) lifts CEO Geordan Pursglove base salary to $360k - Stock Titan
Lixte Biotechnology boosts CEO Geordan Pursglove's base salary to $360,000 - TradingView
Lixte Biotechnology stock faces scrutiny amid stalled pipeline progress and biotech sector volatilit - AD HOC NEWS
Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN
Guidance Update: Is Lixte Biotechnology Holdings Inc a stock for growth or value investorsWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Breakout Move: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proofWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Faces Short-Term Pressure Amid Strong Rising Trend an - AD HOC NEWS
Bond Watch: Does Lixte Biotechnology Holdings Inc align with a passive investing strategyOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
LIXTE Biotechnology and Liora Technologies Partner to Advance Combined Cancer Treatment Approach - citybuzz -
Aug PostEarnings: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proof2026 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Trades Steadily Amid Clinical-Stage Oncology Focus - AD HOC NEWS
Is Lixte Biotechnology Holdings Inc stock technically oversold2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
LIXTE Biotechnology Expands Ovarian Cancer Trial Through MD Anderson and GSK Partnership - citybuzz -
Lixte Amends Share Exchange, Clarifies Liora Ownership Structure - The Globe and Mail
Lixte Biotechnology Enters Amended Share Exchange to Consolidate Liora Ownership With Orbit Capital - TradingView
Lixte (NASDAQ: LIXT) restates Liora share exchange and Orbit’s 20% stake - Stock Titan
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline - TipRanks
LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research - TradingView
Powell Max Limited Successfully Repositions for Its Next Phase of Growth - The Manila Times
Aug Sectors: Whats the profit margin of Lixte Biotechnology Holdings IncWeekly Profit Recap & Capital Efficient Trading Techniques - baoquankhu1.vn
Trade Report: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Volatility Watch: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity WarrantWeekly Stock Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Why Lixte Biotechnology Holdings Inc. stock attracts high net worth investorsMarket Risk Analysis & Safe Entry Point Alerts - Naître et grandir
Wall Street Recap: Why is Lixte Biotechnology Holdings Inc Equity Warrant stock going downDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
MACD Signal: How does Lixte Biotechnology Holdings Inc Equity Warrant perform in inflationary periodsTrade Analysis Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
LIXTW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LIXTE Biotechnology (NASDAQ: LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - Digital Journal
LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment - Digital Journal
Downgrade Watch: Will Lixte Biotechnology Holdings Inc stock go up in YEARJuly 2025 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Should I Buy LIXT? LIXT 2026 AnalysisIntellectia AI™ - Intellectia AI
LIXTWLixte Biotechnology Hldgs Inc Latest Stock News & Market Updates - Stock Titan
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Sponsors Good Health Mind, Body and Soul Summit - USA Today
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK - USA Today
Should I invest in Lixte Biotechnology Holdings Inc. before earningsJuly 2025 Chart Watch & Expert Approved Trade Ideas - mfd.ru
Is Lixte Biotechnology Holdings Inc. stock a value trap2025 Stock Rankings & Accurate Entry and Exit Point Alerts - mfd.ru
Why Lixte Biotechnology Holdings Inc. stock could rally in 2025July 2025 WrapUp & Precise Swing Trade Alerts - mfd.ru
What is the next catalyst for Lixte Biotechnology Holdings Inc. Equity WarrantWeekly Loss Report & Verified Trade Idea Suggestions - mfd.ru
Will Lixte Biotechnology Holdings Inc. stock go up in YEARJuly 2025 Summary & Community Verified Trade Signals - mfd.ru
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary By Investing.com - Investing.com India
LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary - NewMediaWire
Lixte Elevates Liora Leadership to Advance Proton Therapy - TipRanks
LIXTE Biotechnology appoints Sidney Braun to lead Liora subsidiary - Investing.com
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):